Tumour-wide RNA splicing aberrations generate actionable public neoantigens

Abstract excerpt

Abstract T cell-based immunotherapies hold promise in treating cancer by leveraging the immune system’s recognition of cancer-specific antigens 1 . However, their efficacy is limited in tumours with few somatic mutations and substantial intratumoural heterogeneity 2–4 . Here we introduce a previously uncharacterized class of tumour-wide public neoantigens originating from RNA splicing aberrations in diverse...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to CAR-T cell therapy research
• Share to Immunotherapy and Immune Responses